Lexeo Therapeutics, Inc. Common Stock

NASDAQ:LXEO

Biotechnology

Healthcare
$2.95 -0.94%

-$0.05 today

Market cap
$244.23M
Beta
1.39
P/E (TTM)
-4.6
EPS (TTM)
-$1.08
52W Low $3.60High $10.99

Volume 1.76M

Average 0.86M

Returns on capital

Lexeo Therapeutics, Inc. Common Stock management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-40.5%

avg 8.9%

ROIC

-42.9%

avg -50.6%

ROA

-37.2%

avg -44.5%

Analysis

ROA is currently the strongest return metric at -37.2% versus its period average of -44.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jose Manuel Otero

Chief Operating OfficerUSD 2.99M4754.75K0.07%

R. Nolan Townsend

Chief Executive Officer & DirectorUSD 991.47K45——

Louis Tamayo

Chief Financial Officer & Principal Accounting OfficerUSD 638.9K49——

Ronald G. Crystal

Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board————

Ashley Kaplowitz

Head of Capital Markets————

Keith Wonnacott

Senior Vice President of Regulatory Affairs————

Narinder Bhalla FACC FSCAI

Chief Medical Officer—62——

Ryan McHenry

Vice President & Corporate Controller————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 24, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

12

$720,693.49

Net Transaction Value

−$720,693.49

Net selling

Most Active

Townsend Richard Nolan

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 18, 26

Otero Jose Manuel

Direct

Sell$6.5K
Aug 18, 26

Tamayo Louis Edward

Direct

Sell$20.2K
Aug 18, 26

Townsend Richard Nolan

Direct

Sell$16.6K
Jul 1, 26

Tamayo Louis Edward

Direct

Sell$20.8K
Jul 1, 26

Bhalla Narinder Pal

Direct

Sell$98.6K
Jul 1, 26

Otero Jose Manuel

Direct

Sell$20.9K
Jul 1, 26

Townsend Richard Nolan

Direct

Sell$116.2K
May 18, 26

Otero Jose Manuel

Direct

Sell$6.6K
May 18, 26

Townsend Richard Nolan

Direct

Sell$16.9K
Apr 6, 26

Townsend Richard Nolan

Direct

Sell$313.1K

1–10 of 12

Summary

Insiders reported 0 buys worth $0.00 and 12 sells worth $720,693.49 over the last 12 months. That adds up to net selling of $720,693.49. Townsend Richard Nolan was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Lexeo Therapeutics, Inc. Common Stock compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about LXEO's management, answered from reported figures.

Who manages LXEO?

Lexeo Therapeutics, Inc. Common Stock (LXEO) lists 8 active executives. The top listed executive is Ronald G. Crystal, Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board.

Are LXEO insiders buying or selling?

Recent insider activity shows net buying of $45.48M.